#3101 LOW CIRCULATING LEVELS OF CARDIO-REGULATORY MIRNAS PREDICT WORSE OUTCOMES IN HEMODIALYSIS PATIENTS

Abstract Background and Aims Patients with end stage renal disease (ESKD) on hemodialysis (HD) have a high risk of cardiovascular (CV) events, this being mostly related to the presence uraemic cardiomyopathy. A deregulation in expression various microRNAs (miRNAs: non-coding RNAs that regulate post-transcriptional gene expression) has previously been implied pathological cardiac remodelling. Nevertheless, scarce evidence accrued so far possible significance CV morbidity mortality HD patients, relationship uremic Method We run pilot, prospective, multicentre cohort study involving 74 ESKD patients undergoing chronic from 3 different hospitals Italy Greece. underwent thorough clinical, laboratory echocardiography assessment were then prospectively followed for 24 months or until occurrence composite endpoint (CV all-cause) non-fatal events. Through systematic review literature, we identified small panel miRNAs (30a-5p, 23a-3p,451a let7d-5p), which levels are known be altered either major disorders kidney failure. measured blood group matched healthy controls. Results 23a-3p (p<0.0001), 451a (p = 0.001), 30a-5p 0.003) let7d-5p <0.0001) all reduced as compared Significant correlations found between indexes dysfunction such Vmax, TAPSE E/E’, well some other parameters uric acid, sodium, potassium, HDL CRP. During follow-up, 30/74 (40.5%) reached endpoint. In these individuals, but significantly at baseline (p<0.0001). As showed by multivariate Cox-regression analyses, 23a-3p, 451a, predictors (HR ranging 0.943 0.995; p 0.05 0.02) Kaplan-Meier analyses confirmed faster progression subjects below an optimal ROC-derived cut-off value 0.001 <0.0001; crude HRs 7.95 8.61; Figure 1). Conclusion Our demonstrated evaluation very circulating (30-5p, 23a–3p 451a) may impart important prognostic information respect risk. Although biological meaning their remains unanswered, preliminary findings set larger investigation generalize usefulness biomarkers, therapeutic targets.